Ansa Biotechnologies
YC W20Emeryville, US · Founded 2018 · Delaware corporation · 72 employees · 9 known investors
Ansa provides an enzymatic DNA synthesis platform that directly synthesizes complex sequences up to 900 bp and delivers constructs up to 50 kb without assembly-based methods. It serves scientists in gene and cell therapies, antibody discovery, CDMOs, and agrigenomics.
Founders & leadership· Y Combinator alumni (W20)
Ansa Biotechnologies was founded in 2018 by Dan Lin-Arlow, Sebastian Palluk, Daniel Lin-Arlow, and Daniel Hillel Lin-Arlow.
DL
Dan Lin-ArlowinFounder
SP
Sebastian PallukinCo-founder and CTOFounder of Ansa Biotechnologies, which offers an enzymatic DNA synthesis platform that directly synthesizes complex sequences and delivers longer constructs without assembly-based methods for uses such as gene and cell therapies, antibody discovery, and agrigenomics.
DL
Daniel Lin-ArlowCo-founder
DH
Daniel Hillel Lin-ArlowCo-founder
JT
Jason T. GammackExecutive
Board
YD
Yanniv DoroneBoard director
CZ
Chenny ZhangBoard director
MM
Matthew McManusBoard director
Investors · 9
Carbon SiliconCarson City · $100K – $500Kvia Nish Bhat · inferred
Dauntless VenturesHolladay
Fifty YearsSan Francisco · $250K – $2M
MetaplanetTallinn · $500K – $10M
Y CombinatorSan Francisco · $500K
Fall Line CapitalreportedSan Francisco
Horizons VenturesreportedHong Kong · $1M – $110M
HumboldtreportedNew York · $100K – $5M
RA CapitalreportedBoston
Funding
SEC filings, press & company announcements$178.6M disclosed across 5 of 6 rounds · 2020–2025
- $54.4MSeries BOct 2025 · 3 sourcesSource ↗
▶$46.4MraisedDec 2025 · 41 investors · BiotechnologyRule 506(b)
▶$46.4MraisedDec 2025 · 41 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason T. GammackExecutive Officer, Director
- Yanniv DoroneDirector
- Daniel Lin-ArlowExecutive Officer, Director
- Chenny ZhangDirector
- Matthew McManusDirector
- Sebastian PallukExecutive Officer
- Offering amount
- $56.9M
- Amount sold
- $46.4M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$68MraisedMay 2022 · 28 investors · BiotechnologyRule 506(b)
▶$68MraisedMay 2022 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel Lin-ArlowExecutive Officer, Director
- Sebastian PallukExecutive Officer, Director
- Lily LiDirector
- Offering amount
- $76.7M
- Amount sold
- $68M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$5MraisedOct 2021 · 7 investors · BiotechnologyRule 506(b)
▶$5MraisedOct 2021 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sebastian PallukExecutive Officer, Director
- Daniel Lin-ArlowExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$4.7MraisedJul 2020 · 24 investors · BiotechnologyRule 506(b)
▶$4.7MraisedJul 2020 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sebastian PallukExecutive Officer, Director
- Daniel Hillel Lin-ArlowExecutive Officer, Director
- Offering amount
- $9.2M
- Amount sold
- $4.7M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapGenewiz47 shared keywordsGENEWIZ, part of Azenta Life Sciences, provides genomics laboratory services including next-generation and Sanger sequencing, gene synthesis, oligo synthesis, plasmid DNA preparation, proteomics, and GLP-compliant and clinical services. It serves researchers and life science organizations working in areas such as cancer genomics, cell and gene therapy, synthetic biology, and infectious disease.
Fiveable41 shared keywordsFiveable provides AI-powered exam preparation for AP classes, offering practice questions with automated scoring and personalized study tools for high school students.
Companies competing with Ansa Biotechnologies for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2021 | $994.7K |
| National Science Foundation | Phase I | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Ansa Biotechnologies do?
- Ansa provides an enzymatic DNA synthesis platform that directly synthesizes complex sequences up to 900 bp and delivers constructs up to 50 kb without assembly-based methods. It serves scientists in gene and cell therapies, antibody discovery, CDMOs, and agrigenomics.
- Who founded Ansa Biotechnologies?
- Ansa Biotechnologies was founded by Dan Lin-Arlow, Sebastian Palluk, Daniel Lin-Arlow, Daniel Hillel Lin-Arlow in 2018.
- Who are Ansa Biotechnologies's investors?
- Ansa Biotechnologies's investors include Carbon Silicon, Dauntless Ventures, Fifty Years, Metaplanet, Y Combinator, Fall Line Capital, Horizons Ventures, Humboldt and 1 more.
- How much funding has Ansa Biotechnologies raised?
- Ansa Biotechnologies has disclosed $178.6M raised across 5 of its 6 known rounds.
- Where is Ansa Biotechnologies headquartered?
- Ansa Biotechnologies is headquartered in Emeryville, US.